Jocelyn Solis-Moreira

Feature Writer

B.Sc. Integrative Neuroscience, M.Sc. Psychology

Jocelyn Solis-Moreira graduated with a Bachelor's in Integrative Neuroscience, where she then pursued graduate research looking at the long-term effects of adolescent binge drinking on the brain's neurochemistry in adulthood. She is adept at translating and summarizing complex study findings in all medical fields with a particular interest in neurodegenerative diseases, cancer research, infectious diseases, and public health. As a freelance writer, her work spans from news articles and feature articles to evergreen explainers across many publications. Her overall goal is to make science accessible for all.

Articles from Jocelyn

Study finds limited association between vitamin D and improved COVID-19 outcomes

New research shows a lack of an association between Vitamin D deficiency and the number of COVID-19 cases, recoveries, or mortality rates in European countries.

11 Mar 2021

Single mRNA vaccine dose may be enough for those previously exposed to SARS-CoV-2

New research supports the notion that those who have recovered from COVID-19, caused by SARS-CoV-2 infection, may only need one dose of an mRNA vaccine to boost immunity.

10 Mar 2021

Neutralizing antibodies may be evolving to keep up with SARS-CoV-2 mutations

Viruses evolve under increased pressure, and new research from The Rockefeller University and University of Massachusetts Medical School in the U.S. suggests our antibodies can as well.

10 Mar 2021

SARS-CoV-2's amyloid-driving nucleoprotein could inform future therapeutic research

New research led by researchers at the University of California Los Angeles and the University of Texas Southwestern Medical Center in the US suggests that functional amyloid fibrils could play an integral role in developing COVID-19 treatments.

9 Mar 2021

Greater cross-neutralization against UK SARS-CoV-2 variant in vaccinated individuals with prior infection

A team of researchers in Spain has observed that, of those who have been vaccinated against SARS-CoV-2, higher titers of neutralizing antibodies for the B.1.1.7 variant (originating in the UK) were present in those who had previously been infected with the virus.

9 Mar 2021

Impairments in immune response contribute to severe COVID-19

New research by a team of scientists at University Hospital RWTH Aachen in Germany and Erasmus Medical Centre in The Netherlands characterized changes in CD8+ T cells in response to SARS-CoV-2.

8 Mar 2021

Study confirms B.1.1.7 variant of SARS-CoV-2 is more transmissible

A new modeling study published in the journal Science estimates the B.1.1.7 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant is 43% to 90% more transmissible than previous coronavirus variants. The variant was initially found in Southeast England last fall.

7 Mar 2021

Saliva testing has high accuracy in detecting early cases of SARS-CoV-2

New research finds saliva testing has a high sensitivity for detecting severe acute respiratory syndrome 2 (SARS-CoV-2) in both symptomatic and asymptomatic patients.

7 Mar 2021

Preclinical study finds immune benefit in unrefrigerated Soligenix coronavirus vaccines

A new study reports positive outcomes from two new vaccine candidates. The research, led by Axel T. Lehrer from the University of Hawaii at Manoa, studied mice's immune response when administered the CoVaccine HT adjuvant with an insect-cell expressed SARS-CoV-2 spike protein ectodomain.

4 Mar 2021

Study explains how the B.1.1.7 SARS-CoV-2 variant is more transmissible

New research led by Thushan I. de Silva from the University of Sheffield proposes that increases in subgenomic RNA (sgRNA) expression cause increased viral transmissibility and subsequent infection. They suggest the ORF9 protein, found in high amounts of sgRNA, could be regulating interferon responses.

4 Mar 2021